Caricamento...

Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds

Introduction. Given its efficacy and safety, NexoBrid™ (NXB) has become part of our therapeutic options in burns treatment with satisfactory results. However, no cost analysis comparing NXB to the standard of care (SOC) has been carried out as of today. Aim. To assess the cost of treatment with NXB...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Biomed Res Int
Autori principali: Giudice, Giuseppe, Filoni, Angela, Maggio, Giulio, Bonamonte, Domenico, Vestita, Michelangelo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Hindawi Publishing Corporation 2017
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5331316/
https://ncbi.nlm.nih.gov/pubmed/28293640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/9567498
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !